Cite
HARVARD Citation
Röllig, C. et al. (2015). Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet oncology. 16 (16), pp. 1691-1699. [Online].